SLC5A2 and liver dysplastic nodule: Although some reports suggest that renin-angiotensin-aldosterone system inhibitors (RAASi) [8, 9], sodium-glucose cotransporter 2 inhibitors (SGLT-2i) [10–12], glucagon-like peptide-1 receptor agonists (GLP-1 RA) [10, 13, 14], and endothelin receptor antagonists (ERAs) [15–17] have renoprotective properties in delaying the progression of DN, they cannot stop DN progression to end-stage renal failure.